Mendel vs Triomics (2026)
Two chart abstraction platforms with real technical arguments, split by scope. Mendel is disease agnostic and makes the sharper architectural claim, pairing language models with symbolic reasoning over a clinical hypergraph precisely because generation alone produces confident errors in abstraction, and it can run inside the customer's own environment. Triomics is oncology only and better evidenced for it, with peer reviewed validation in a recognised journal, every match traced back to the pathology and biomarker behind it, and the deepest workflow integration in the trials category. For a cancer centre where oncology is the research programme, Triomics does the harder version of the job and shows its working. For an academic centre running research across specialties, or one that cannot let records leave its environment, Mendel is the more flexible platform.
- The architecture is deliberately hybrid, pairing language models with symbolic reasoning over a clinical hypergraph because generation alone produces confident abstraction errors.
- It can be hosted inside the customer's own environment, which is the strongest residency position among the trial and abstraction vendors here.
- The capability serves chart review, cohort building and observational research as well as prescreening, so one platform covers several research functions.
- It is oncology tuned rather than disease agnostic, and oncology eligibility is where the reasoning is hardest because the decisive detail sits in pathology and biomarker text.
- Peer reviewed validation in a recognised digital medicine journal is the strongest evidence position in the trials category.
- Every match is traced back to the pathology, biomarker and note that produced it, and the output lands where the oncology team already works.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Mendel and Triomics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Mendel | Triomics |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | 2016 | 2021 |
| Headquarters | San Jose, California, United States | San Francisco, California |
| Website | mendel.ai | triomics.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Mendel its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Triomics, Mendel grades higher on Deployment Model and Data Residency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Triomics its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Mendel, Triomics grades higher on several axes, including Model Supply Chain Disclosure, Clinical and Operational Evidence and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Mendel or Triomics?
On the axes where the AI Health Index separates them, Mendel grades higher on Deployment Model and Data Residency, and Triomics grades higher on several axes, including Model Supply Chain Disclosure, Clinical and Operational Evidence and HIPAA and BAA Posture. Triomics leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Mendel and Triomics differ most?
The widest separation the AI Health Index records between Mendel and Triomics is on Deployment Model and Data Residency, where Mendel grades A and Triomics grades B. That axis sits in the Integration and Deployment group, so it should carry the most weight for a buyer whose binding constraint is how the product lands in the stack already in place.
Where do Mendel and Triomics grade the same?
The AI Health Index grades Mendel and Triomics the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both read the whole chart to answer specific clinical questions, so the failure that matters is the eligible patient who never surfaced rather than a fabricated one, and neither publishes a false negative rate for eligibility screening. Neither publishes a security attestation or a trust centre.
Trial and cohort work also inherits documentation bias: patients with sparse or fragmented records are systematically less likely to be found, and that population overlaps with the one research already under enrols. Neither publishes pricing, though both frame the economics against the cost of clinician chart review, which is the right comparison to test against your own abstraction costs.